Basilea Pharmaceutica AG (BSLN) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Basilea Pharmaceutica AG stock CHF 78.10, price CHF 71.00, upside +10.0%, quality 64 out of 100. Rating: fairly valued. Calculated from audited financials with 24 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 8, 2026.
How to read this chart
60‑month range CHF 29.95 – CHF 73.70 · fair‑value band CHF 52.66 – CHF 101.54 · the CHF 71.00 price screens below the CHF 78.10 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 4 fiscal years are left out: there the valuation rested on only a fraction of the usual models. As of Nov 8, 2026.
Follow Basilea Pharmaceutica in your weekly email
Every Wednesday you see whether Basilea Pharmaceutica is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Basilea Pharmaceutica AG is a Swiss commercial-stage biotech company focused on developing and commercializing treatments for severe bacterial and fungal infections.
Show moreShow less
The company offers Cresemba (isavuconazole), an intravenous and oral antifungal for the treatment of invasive aspergillosis and mucormycosis; and Zevtera (ceftobiprole), an antibiotic for the treatment of pneumonia, Staphylococcus aureus bacteremia (SAB), acute bacterial skin, community-acquired bacterial pneumonia, and skin structure infections (ABSSSI). The company also has a clinical-stage pipeline of anti-infective assets that include fosmanogepix, a broad-spectrum antifungal in phase 3 development for invasive mold infections; ceftibuten-ledaborbactam etzadroxil, a phase 3 - ready oral antibiotic for the treatment of complicated urinary tract infections (cUTI); BAL2062, a candidate for invasive aspergillosis currently advancing toward phase 2 clinical development; and BAL2420, a preclinical-stage antibiotic targeting severe enterobacteriaceae infections.
The company has a strategic collaboration with Prokaryotics, Inc for the development of broad-spectrum antifungal targeting drug-resistant pathogens through a differentiated mechanism of action; and Phare Bio, a biotech social venture to leverage generative artificial intelligence (AI) to transform antibiotic discovery.
Basilea Pharmaceutica AG was founded in 2000 and is headquartered in Allschwil, Switzerland.
Stock analysis
Basilea Pharmaceutica AG (BSLN) currently trades at CHF 71.00, while our model-based Fair Value estimate is CHF 78.10, so the stock looks roughly fairly valued today (gap 9.1%).
Show more
Valuation
Bull case: the Growth DCF group reads highest at a median of CHF 99.69 per share, and 13 of the 24 models we run sit above the CHF 71.00 price.
Bear case: the Asset-Based group reads lowest at CHF 7.88, and 11 of the 24 models stay below the price. Data coverage for this calculation is medium.
Scenario range: CHF 52.66 (bear) to CHF 101.54 (bull), the price of CHF 71.00 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 64/100 (solid quality), in the Healthcare sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Basilea Pharmaceutica AG reported revenue of CHF 232M in FY2025 versus CHF 148M in FY2021, a compound +11.9%/yr. Reported net income was CHF 40.2M in FY2025.
Key figures
Market cap CHF 981M Small · P/E ratio 17.8 · P/S ratio 3.96 · EPS (TTM) CHF 3.99 · Net margin 21.2% · Return on equity 39.5% · Return on assets (EBIT) 12.4% (5-year average) · Operating margin 26.9%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 85 out of 100 (low confidence).
What moves the price
The share trades about 4% below its 52-week high and 58% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at 10%, BSLN screens cheaper than that median.
Fair Value models
BearCHF 52.66Fair Value CHF 78.10BullCHF 101.54
Price CHF 71.00 · Upside +10.0%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (CHF 3.41 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.97/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+11.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+16.3%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+12.7%
Start year 2020 (pandemic). Over 10 years: +16.0% a year
Revenue growth 23 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+35.8%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 3 years) (mathematically smoothed) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 3 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Smoothed = median of all growth paths between the years of the window (trend line on the logarithm of earnings per share): a single extreme year cannot distort the rate. The reported figure stays in the tooltip.
+66.8%
Earnings growth per share plus dividend.
Earnings per share, growth per year+66.8%
Dividend (yield on the price)0.0%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.−18% → 22%
2025 sits 209% above its own trend. The rate follows the median trend of the last 3 years, not that single year.
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far and less than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+4.1%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+7.3%
Yearly sales growth analysts expect, extended to five years.
After inflation (Switzerland: IMF forecast 0.6% a year to 2030, 0.8% from 2016 to 2025) that is about +3.5% a year for the price and +6.7% for the forecasts.
News mood ⓘNews mood, the average tone of recent news (54 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation.Positive
Recent news coverage is more positive than average.
Compare Basilea Pharmaceutica AG with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 558 stocks
Beats the industry median on 11/13 measures
Overall it ranks above its industry peers.
Valuation
Quality Score64 · Top 25%
Fair Value upside+10.0% · Top 25%
Profitability
Return on equity (12 months)39.5% · Top 25%
Return on assets14.3% · Top 25%
Net margin (12 months)21.2% · Top 25%
Operating margin (12 months)26.9% · Top 25%
Growth and dividend
Revenue growth (quarter YoY)14.5% · Above median
Balance sheet
Debt / equity0.59× · Highest 25%
Valuation Multiplesvs Biotechnology median · lower = cheaper
P/E (12 months)17.8× · Cheaper than median
P/B7.66× · Priciest 25%
P/S (12 months)3.96× · Cheaper than median
Price / free cash flow (fiscal year)16.5× · Cheaper than median
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Basilea Pharmaceutica AG Fair Value". https://www.fairvalue-calculator.com/stock/BSLN
Frequently asked questions
Is Basilea Pharmaceutica AG (BSLN) overvalued or undervalued?
As of Nov 8, 2026, our model estimates a fair value of CHF 78.10 versus a price of CHF 71.00, about +10% upside (fairly valued).
What is the fair value of BSLN?
Our model-based fair value for Basilea Pharmaceutica AG is CHF 78.10 (as of Nov 8, 2026), built from audited fundamentals. The current price: CHF 71.00.
What is the quality score of BSLN?
Basilea Pharmaceutica AG has a Quality Score of 64/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Basilea Pharmaceutica AG (BSLN)?
Our model-based price target is the fair value of CHF 78.10 (as of Nov 8, 2026) from 24 valuation models. Cautious scenario CHF 52.66, optimistic scenario CHF 101.54. It is a calculation from audited fundamentals, not an analyst target.
What is the Basilea Pharmaceutica AG stock forecast for 2026?
Our models put fair value at CHF 78.10, about +10% upside versus a price of CHF 71.00 (fairly valued). Cautious scenario CHF 52.66, optimistic scenario CHF 101.54. The calculation is refreshed regularly with new filings.
What is the revenue of Basilea Pharmaceutica AG (BSLN)?
Basilea Pharmaceutica AG reported trailing-twelve-month revenue of about CHF 247M (latest available figure, as of Nov 8, 2026).
What growth is priced into Basilea Pharmaceutica AG (BSLN)?
For today's price to be fair in a discounted-cash-flow model, Basilea Pharmaceutica AG would have to grow free cash flow by +4.1 % per year for five years (discount rate 9.6 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +12.7 % per year. As of Nov 8, 2026.
What discount rate (WACC) does the fair value of BSLN use?
Our models discount Basilea Pharmaceutica AG at 9.6 %: a base by market capitalisation (small), damped by beta 0.37, country premium for Switzerland. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Basilea Pharmaceutica AG that is +4.1 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (9.6 %) and the same formula as our fair value.
How much growth has Basilea Pharmaceutica AG (BSLN) delivered so far?
Over the past 5 years revenue at Basilea Pharmaceutica AG grew +12.7 % a year. The price currently implies free-cash-flow growth of +4.1 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Basilea Pharmaceutica AG (BSLN) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into Basilea Pharmaceutica AG (+4.1 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Basilea Pharmaceutica AG (BSLN)?
The free-cash-flow yield on the price is 6.07 %: that much free cash flow Basilea Pharmaceutica AG produces per unit of market value. When it exceeds the discount rate of our models (9.6 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Basilea Pharmaceutica AG (BSLN)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Basilea Pharmaceutica AG it is CHF 78.10 per share (as of Nov 8, 2026), against a price of CHF 71.00. It is the blended result of 24 valuation models in 7 families (DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Basilea Pharmaceutica AG stock overvalued or undervalued in 2026?
As of Nov 8, 2026, BSLN trades below its calculated fair value: price CHF 71.00, fair value CHF 78.10, a gap of about +10% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of BSLN?
No. The price is what the market pays today (CHF 71.00); the fair value is what the company's own numbers justify (CHF 78.10). For Basilea Pharmaceutica AG the two are CHF 7.10 per share apart. That gap is exactly why we show both numbers side by side.
How much is Basilea Pharmaceutica AG worth?
The market values Basilea Pharmaceutica AG at about CHF 981M (market capitalisation, as of Nov 8, 2026). Per share that is CHF 71.00; our models calculate a fair value of CHF 78.10 per share.
What do the bullish and bearish scenarios say about BSLN?
Our models span a range for Basilea Pharmaceutica AG: cautious scenario CHF 52.66, base CHF 78.10, optimistic CHF 101.54 per share (as of Nov 8, 2026, price CHF 71.00). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of BSLN?
Basilea Pharmaceutica AG trades at a price-to-earnings ratio of 17.8 (as of Nov 8, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of CHF 78.10 is built from several models across several years. Other multiples: P/B 7.7, P/S 4.0, EV/EBITDA 16.9.
How solid is the balance sheet of Basilea Pharmaceutica AG (BSLN)?
Balance-sheet figures for Basilea Pharmaceutica AG (as of Nov 8, 2026): return on equity 39.5%, debt of 0.59 per unit of equity. They feed the Quality Score of 64/100, which measures business quality independently of the share price.
How far is BSLN from its 52-week high?
Basilea Pharmaceutica AG trades at CHF 71.00, about 4% below its 52-week high of CHF 73.70 and 58% above the low of CHF 44.90 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of CHF 78.10 is for.
Which stocks are comparable to Basilea Pharmaceutica AG?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, CSL Limited, argenx SE, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Basilea Pharmaceutica AG stock attractive at the current price?
The data as of Nov 8, 2026: price CHF 71.00, calculated fair value CHF 78.10 (+10%), Quality Score 64/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of BSLN calculated?
We run Basilea Pharmaceutica AG through 24 models from 7 families: DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of CHF 78.10 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0% above its aggregate fair value. Basilea Pharmaceutica AG currently trades 9% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Basilea Pharmaceutica AG (BSLN)?
The closing price on Nov 6, 2026 was CHF 71.00. Our model-based fair value is CHF 78.10, about +10% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Basilea Pharmaceutica AG right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. A fairly wide model range (CHF 52.66 to CHF 101.54) leaves room in how you read the outcome.
Key figures of Basilea Pharmaceutica AG
How large is the market capitalisation of Basilea Pharmaceutica AG (BSLN)?
The market capitalisation of Basilea Pharmaceutica AG is CHF 981M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Basilea Pharmaceutica AG (BSLN)?
The price-to-sales ratio of Basilea Pharmaceutica AG is 3.96 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Basilea Pharmaceutica AG (BSLN)?
Earnings per share at Basilea Pharmaceutica AG are CHF 3.99 (price ÷ EPS = P/E 17.8). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Basilea Pharmaceutica AG (BSLN)?
The net margin of Basilea Pharmaceutica AG is 21.2% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Basilea Pharmaceutica AG (BSLN)?
The return on equity (ROE) of Basilea Pharmaceutica AG is 39.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Basilea Pharmaceutica AG (BSLN)?
On an EBIT basis the return on assets of Basilea Pharmaceutica AG is 12.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Basilea Pharmaceutica AG (BSLN)?
The operating margin of Basilea Pharmaceutica AG is 26.9% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Basilea Pharmaceutica AG (BSLN)?
Revenue at Basilea Pharmaceutica AG is growing +14.5% versus a year earlier (3y avg +16.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Basilea Pharmaceutica AG (BSLN)?
Earnings per share at Basilea Pharmaceutica AG are growing +64.4% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Basilea Pharmaceutica AG (BSLN) carry?
The net debt of Basilea Pharmaceutica AG is CHF 71.3M (fiscal year 2025, ≈ 1.2 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Basilea Pharmaceutica AG in the live analysis
One click puts Basilea Pharmaceutica AG on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Some data
Nov 8, 2026